TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04697368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Upper Limb Rehabilitation
Description: The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Upper Limb Rehabilitation
Description: The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
Study: NCT04134884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
Study: NCT01633138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy - Standard
Description: Computerized cognitive remediation therapy provided three times per week for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy plus Contingency Management
Description: Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
Study: NCT00721929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging
Study: NCT02282059

Intervention type: DRUG
Intervention: sunitinib
Description: subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
Study: NCT01657656

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study: NCT01340014

Intervention type: DRUG
Group type: OTHER
Intervention: Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
Study: NCT03626311

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AKBM-3031
Description: Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
Study: NCT01657656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT02612350

Intervention type: GENETIC
Intervention: ctDNA Analysis for the Detection of Genetic Mutations
Description: Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
Study: NCT04104087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Description: enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Study: NCT01921114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioFlo™ Peripherally Inserted Central Catheter (PICC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard® Dual-Lumen PowerPICC SOLO2®
Study: NCT01226485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taladegib
Description: Administered IV
Study: NCT01765452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Closone
Description: 75mg/100mg, 8weeks, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix with Astrix
Description: 75mg, 100mg a day, 8weeks, PO
Study: NCT01181219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CXL without epithelial removal
Description: UV-radiation of a Riboflavin saturated cornea without prior epithelial removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CXL with epithelial removal
Description: UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
Study: NCT01827098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Regeneration
Description: Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Regeneration
Description: Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
Study: NCT01531907

Intervention type: OTHER
Intervention: Study visit procedures
Description: Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.

Intervention type: OTHER
Intervention: Study visit procedures
Description: Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.
Study: NCT04162236

Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocardiographyc ultrasound
Description: * Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocardiographyc ultrasound
Description: * Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays.
Study: NCT04104087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Description: enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
Study: NCT04794114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental ankle foot orthosis
Description: On the basis of an accurate kinetic and kinematic analysis, a customized orthosis in thermoplastic material with carbon inserts will be created that will make the brace more elastic and facilitate the child's motor activities.
Study: NCT04162236

Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocardiographyc ultrasound
Description: * Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays.
Study: NCT00566839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: awake nonresectional LVRS
Description: Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonawake resectional LVRS
Description: Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
Study: NCT00002721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug resistance inhibition treatment
Study: NCT00812721

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preservative Free Saline
Description: One drop will be instilled into each eye once
Study: NCT04794114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional ankle foot orthosis
Description: The normal afos in thermoplastic material, while guaranteeing an ankle joint stability, make the joint more rigid and reduce the elasticity of movement especially during running, jumping and sprinting.
Study: NCT00812721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: One drop will be instilled into each eye once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Moderate/Severe
Description: One drop will be instilled into each eye once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: One drop will be instilled into each eye once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: One drop will be instilled into each eye once
Study: NCT02190552

Intervention type: DEVICE
Intervention: EmboTrap® Revascularization Device
Study: NCT02602353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen Pain Patch
Description: One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: One Placebo Patch applied daily for 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: No Treatment
Description: No Treatment for 3 days
Study: NCT00605566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
Study: NCT02185677

Intervention type: OTHER
Intervention: Clinical evaluation

Intervention type: OTHER
Intervention: Clinical evaluation

Intervention type: OTHER
Intervention: neuropsychological battery test

Intervention type: OTHER
Intervention: neuropsychological battery test

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy recording will be performed during 7 days after inclusion.

Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy recording will be performed during 7 days after inclusion.
Study: NCT01357109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg bid for two weeks and 125 mg bid for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo bid
Study: NCT04700475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser
Description: Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland .

Intervention type: DRUG
Group type: OTHER
Intervention: citric acid solution
Description: citric acid solution applied as a mouth rinse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citric acid solution
Description: citric acid solution applied as a mouth rinse
Study: NCT00263484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study: NCT00469859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lestaurtinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lestaurtinib
Description: Given orally
Study: NCT00996814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Ethics Intervention
Description: The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
Study: NCT02970357

Intervention type: OTHER
Group type: OTHER
Intervention: DIAPASON Questionnaire
Description: 50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~* what is diabetes~* Monitoring~* Hypoglycemia and Hyperglycemia~* Nutrition~* Insuline

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WHO-5
Description: 5 item questionnaire of the World Health Organization about quality of life
Study: NCT02956356

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control treatment + oral glucose
Description: Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIOSTAT treatment + oral glucose
Description: SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control treatment + meal intake
Description: Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIOSTAT treatment + meal intake
Description: SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
Study: NCT04302649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peritoneal dialysate at 37°C temperature
Description: during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
Study: NCT03717077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: learned resourcefulness intervention
Description: The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
Study: NCT03389425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simplified intervention to modify physical activity, lifestyle, and eating behavior
Description: 16 week, behavioural weightloss intervention.